Page 1 of Clinical Trials for Hydroxydaunomycin hydrochloride, 1352 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Terminated
MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Last Updated: March 16, 2012
Condition(s): Ovarian Cancer
2
Recruiting
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Last Updated: November 18, 2011
Condition(s): Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
3
Active, not recruiting
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Last Updated: May 4, 2012
Condition(s): Multiple Myeloma
4
Recruiting
Clinical Trial Of Doxorubicin Versus Trabectedin Plus Doxorubicin In The First Line Treatment Of Patients With Advanced Non Operable And/Or Metastatic Soft Tissue Sarcomas
Last Updated: April 27, 2010
Condition(s): Sarcoma
5
Recruiting
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Last Updated: March 16, 2012
Condition(s): Soft Tissue Sarcoma
6
Completed
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Last Updated: March 15, 2012
Condition(s): Primary Peritoneal Carcinoma; Epithelial Ovarian Carcinoma; Neoplasms, Ovarian; Fallopian Tube Cancer
7
Recruiting
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Last Updated: March 29, 2012
Condition(s): Solid Tumor; Urethral Cancer
8
Not yet recruiting
Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Last Updated: December 9, 2011
Condition(s): Solid Tumors; Lymphomas
9
Recruiting
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Last Updated: April 18, 2012
Condition(s): Sarcoma
10
Active, not recruiting
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
Last Updated: February 16, 2012
Condition(s): Soft Tissue Sarcoma
11
Recruiting
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Last Updated: September 8, 2011
Condition(s): Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
12
Withdrawn
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Last Updated: June 21, 2011
Condition(s): Multiple Myeloma
13
Recruiting
Study Evaluating Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Metastatic Breast Cancer Patients
Last Updated: March 13, 2012
Condition(s): Advanced Solid Tumours; Breast Cancer
14
Completed
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Last Updated: June 8, 2011
Condition(s): Multiple Myeloma; Myeloma; M-Protein; Myeloma Proteins
15
Active, not recruiting
Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
Last Updated: May 18, 2011
Condition(s): Resistant Solid Malignancies
16
Completed
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
Last Updated: November 18, 2008
Condition(s): Primary Breast Cancer
17
Completed
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Last Updated: May 16, 2012
Condition(s): Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
18
Active, not recruiting
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Last Updated: June 14, 2011
Condition(s): High Risk; Breast Cancer; Positive Nodes; Cyclophosphamide; Doxorubicin
19
Active, not recruiting
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed MM
Last Updated: April 12, 2012
Condition(s): Multiple Myeloma
20
Completed
Ph 3 Randomized Study of Telcyta® + Liposomal Doxorubicin Vs Liposomal Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Last Updated: October 24, 2011
Condition(s): Ovarian Neoplasms

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Hydroxydaunomycin+hydrochloride

Page 1 of Clinical Trials for Hydroxydaunomycin hydrochloride, 1352 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About